English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Oligometastatic disease refers to a limited number of metastatic sites that are either “synchronous” when presenting at the time of initial diagnosis or “metachronous” when arising following therapy of the primary tumor. It is hypothesized that the biology of oligometastatic tumors may be different than that of tumors with more widespread metastases (1-3). As such, treatment of oligometastatic sites with local consolidative therapy (LCT) is a topic of interest, and has been increasingly offered in clinical practice. While there is no single definition of this state, it is commonly defined as up to 3–5 sites of metastases (excluding the primary lesion) following induction systemic therapy (1-6).

translational lung cancer research

Local consolidative therapy for oligometastatic patients with stage IV non-small cell lung cancer may improve survival, but unanswered questions remain